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ABSTRACT 
Lactobacilli are normal residents of the human gastrointestinal (GI) tract. Many species 
belonging to the genera Lactobacillus with health beneficial properties have been introduced 
as probiotics. Genetic engineering of Lactobacillus could potentially combine the colonizing 
ability and probiotic effect with an engineered therapeutic function. The aim of this thesis 
was to explore the possibility of using lactobacilli as vectors for delivery of peptides in the GI 
tract for therapy against type 2 diabetes and other immune-related diseases.  
GLP-1, an incretin hormone that can stimulate insulin secretion, is used in the treatment of 
type 2 diabetes. In paper I, we designed and expressed the pentameric GLP-1 (trypsin 
cleavable oligomers) both in a secreted form and anchored on the surface of L. paracasei 
BL23. The pentameric GLP-1 retains its bioactivity both in vitro and in the intestine of 
diabetic rat following digestion by intestinal trypsin. When given by gavage to diabetic rats, 
the non-expressor Lactobacillus showed significant anti-diabetic effect but GLP-1 expression 
did not provide an additional insulinotropic effect possibly due to the low levels produced. 
These results indicate that L. paracasei BL23 itself might be used as an alternative treatment 
method for type 2 diabetes, but further work is needed to increase the expression level of 
GLP-1 by Lactobacillus.   
Interleukin-22 (IL-22) plays a prominent role in epithelial regeneration and protecting 
intestinal stem cells from immune-mediated tissue damage. In paper II, Lactobacillus strains 
were constructed for delivery of IL-22 as a new therapeutic strategy for acute graft-versus-
host disease (GVHD) in the GI tract. The secretion and surface anchoring of mouse IL-22 by 
L. paracasei BL23 was demonstrated and the biological activity of IL-22 produced by 
Lactobacillus was shown in vitro.  
In paper III, we developed a co-expression vector to produce two rotavirus-specific VHH 
antibody fragments in Lactobacillus. Both antibody fragments (ARP1 and ARP3) were 
expressed in secreted and surface anchored forms and their ability to bind to various rotavirus 
serotypes was demonstrated in vitro. This vector was then used in paper IV, to 
simultaneously produce both secreted Interleukin-21 (IL-21) and anchored CD40 ligand 
(CD40L) on the surface of lactobacilli. IL-21/CD40L based stimulation may be a potential 
therapy for IgA deficient patients. In this paper, IL-21(or hybrid IL-21/4) and CD40L were 
expressed individually, or co-expressed in L. paracasei BL23. We showed that Lactobacillus 
expressing IL-21, IL-21/4 and CD40L individually can induce IgA secretion in PBMCs from 
healthy donors.  
This work provides the basis for the use of genetically modified lactobacilli for delivery of 
therapeutic peptides in the GI tact. The delivery strategies could be further developed to 
facilitate easy and inexpensive access to other peptide drugs.    
LIST OF SCIENTIFIC PAPERS 
I. Oral delivery of pentameric glucagon-like peptide-1 by recombinant Lactobacillus
in diabetic rats. 
Lin Y, Krogh-Andersen K, Pelletier J, Marcotte H, Östenson C-G, Hammarström L 
PLoS ONE. 2016 11(9): e0162733.  
II. Oral delivery of Lactobacillus that secretes bioactive interleukin-22. 
Lin Y, Hammarström L, Marcotte H. 
Submitted. 
III. Expression of anti-rotavirus proteins (llama VHH antibody fragments) in 
Lactobacillus: Development and functionality of vectors containing two expression 
cassettes in tandem. 
Günaydın G, Álvarez B, Lin Y, Hammarström L, Marcotte H. 
PLoS ONE. 2014 9(4): e96409. 
IV. Lactobacillus delivery of interleukin-21 and CD40 ligand for treatment of selective 
IgA deficiency. 
Lin Y, Borte S, Appelberg S, Marcotte H, Hammarström L. 
Manuscript. 
  
CONTENTS 
1 INTRODUCTION ........................................................................................................... 1 
1.1 Lactobacillus.......................................................................................................... 1 
1.2 Lactobacillus as a delivery system ........................................................................ 2 
1.2.1 Lactobacillus expression systems ............................................................. 2 
1.2.2 Delivery of therapeutic molecules ............................................................ 3 
1.3 Glucagon-like peptide-1 and type 2 diabetes ........................................................ 4 
1.3.1 Type 2 diabetes .......................................................................................... 4 
1.3.2 Glucagon-like peptide-1 (GLP-1) ............................................................. 4 
1.3.3 GLP-1 based diabetes therapies ................................................................ 6 
1.3.4 Advantages of using lactobacilli for delivery of GLP-1 .......................... 6 
1.4 Interleukin-22 and graft-versus-host disease ........................................................ 7 
1.4.1 Graft-versus-host disease .......................................................................... 7 
1.4.2 Interleukin-22 ............................................................................................ 7 
1.4.3 IL-22 in the treatment of acute GVHD ..................................................... 8 
1.4.4 Advantages of using lactobacilli for delivery of IL-22 ............................ 9 
1.5 Interleukin-21, CD40 ligand and IgA deficiency ................................................. 9 
1.5.1 IgA deficiency ........................................................................................... 9 
1.5.2 IL-21 and IL-4 ......................................................................................... 10 
1.5.3 CD40L ..................................................................................................... 11 
1.5.4 Treatment of IgAD with IL-21 and CD40L ........................................... 11 
1.5.5 Advantages of using lactobacilli for delivery of IL-21 and CD40L ...... 12 
2 AIMS ............................................................................................................................. 13 
2.1 General aim .......................................................................................................... 13 
2.2 Specific aims ........................................................................................................ 13 
3 MATERIALS AND METHODS ................................................................................. 14 
3.1 Bacterial strains and growth conditions .............................................................. 14 
3.2 Synthesis of genes and peptides .......................................................................... 14 
3.3 Cloning in Lactobacillus ..................................................................................... 14 
3.4 Expression analysis ............................................................................................. 15 
3.4.1 Enzyme-linked immunosorbent assay (ELISA)..................................... 15 
3.4.2 Western Blot ............................................................................................ 16 
3.4.3 Flow cytometry ....................................................................................... 17 
3.5 Plasmid loss assay (paper II and IV) ................................................................... 18 
3.6 Protein purification .............................................................................................. 18 
3.7 In vitro model ...................................................................................................... 18 
3.7.1 Insulinotropic activity on HIT-T15 cells (paper I) ................................. 18 
3.7.2 IL-22 biological activity assay (paper II) ............................................... 19 
3.7.3 PBMCs stimulation and enzyme-linked immunospot (ELISPOT) 
assay (paper III) ....................................................................................... 19 
3.8 Animal model (paper I) ....................................................................................... 20 
3.8.1 Intraperitoneal glucose tolerance test (IPGTT) ...................................... 20 
3.8.2 Oral administration of lactobacilli .......................................................... 20 
3.9 Statistics ............................................................................................................... 21 
4 RESULTS AND DISCUSSION ................................................................................... 22 
4.1 Paper I .................................................................................................................. 22 
4.1.1 From GLP-1 to 5×GLP-1 ........................................................................ 22 
4.1.2 5×GLP-1 analogues are bioactive........................................................... 22 
4.1.3 Oral delivery of 5×GLP-1 by Lactobacillus to the diabetic rats ........... 23 
4.2 Paper II ................................................................................................................. 24 
4.2.1 Expression and display of IL-22 ............................................................. 24 
4.2.2 Bioactivity of IL-22 ................................................................................ 25 
4.3 Paper III ............................................................................................................... 25 
4.3.1 Development of co-expression vectors .................................................. 25 
4.3.2 Binding activity of co-expressed VHHs ................................................. 26 
4.4 Paper IV ............................................................................................................... 26 
4.4.1 Lactobacillus constructs and expression of IL-21 (IL-21/4) and 
CD40L ..................................................................................................... 27 
4.4.2 Bioactivity test of IL-21 (IL-21/4) and CD40L ..................................... 28 
5 CONCLUSIONS ........................................................................................................... 30 
6 FUTURE PERSPECTIVES.......................................................................................... 31 
7 ACKNOWLEDGEMENTS .......................................................................................... 35 
8 REFERENCES .............................................................................................................. 37 
 
  
  
LIST OF ABBREVIATIONS 
APF Aggregation promoting factor 
APC 
CFU 
Antigen-presenting cells 
Colony forming unit 
CSR Class-switch recombination 
DNA Deoxyribonucleic acid 
DPP-4 Dipeptidyl peptidase-4 
ELISA Enzyme-linked immunosorbent assay 
ELISPOT Enzyme-linked immunospot 
FITC Fluorescein isothiocyanate 
GI tract Gastrointestinal tract 
GK rat 
GLP-1 
Goto-Kakizaki rat 
Glucagon-like peptide-1 
GRAS Generally regarded as safe 
GVHD Graft-versus-host diseases 
HBC Hyperimmune bovine colostrum 
HLA Human leukocyte antigen 
IBD Inflammatory bowel disease 
Ig Immunoglobulin 
IgAD IgA deficiency 
IPGTT Intraperitoneal glucose tolerance test 
MHC Major histocompatibility complex 
MRS Mann Rogosa Sharpe lactobacilli media 
NICE Nisin controlled gene expression 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PID Primary immunodeficiency diseases 
SCFAs Short-chain fatty acids 
ScFv Single chain fragment variable 
TNF Tumor necrosis factor 
VHH Variable fragment of heavy chain antibody 
  1 
1 INTRODUCTION  
1.1 LACTOBACILLUS 
Lactobacilli are rod-shaped, Gram-positive lactic acid bacteria that are classified as 
“generally recognized as safe” (GRAS) [1]. Lactic acid bacteria are an order of bacteria 
exhibiting an enormous capacity to degrade different carbohydrates and produce lactic acid as 
their main end product [2]. They have been historically used in food fermentation and 
preservation as acidification inhibits the growth of spoilage agents. Lactobacilli are normal 
residents of the gastrointestinal (GI) tract of animals and humans, as shown in Figure 1.1. In 
total, 17 Lactobacillus species can be detected within the human GI tract, although some of 
them are only transient colonizers [3, 4]. The highest density of lactobacilli is found in the 
ileum (up to 108/ml) and in the colon (109/ml). Among them, the dominant colonizers are L. 
gasseri, L. crispatus, L. reuteri, L. casei and L. salivarius [2, 5].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The distribution of lactobacilli in the oral cavity and the gastrointestinal tract. The 
number in bracket shows the total bacterial load in this organ. Data extracted from literature 
[4, 6-8]. 
Probiotics are live bacteria isolated from human or food product defined as “Live 
microorganisms which when administered in adequate amounts confer a health benefit on the 
host” [9]. Lactobacillus is the best-studied probiotic genus, and may modulate metabolic 
activities of the gut microbiota by competing with and displacing pathogens, produce 
antimicrobial agents (such as bacteriocins and short-chain fatty acids (SCFAs)), enhance 
barrier function, induce anti-inflammatory responses or modulate immune response [2, 10]. 
Several studies have demonstrated a beneficial effect of Lactobacillus consumption for 
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mitigation of gastrointestinal (GI) diseases [11-13] such as irritable bowel syndrome (IBS), 
Inflammatory bowel disease (IBD) and rotavirus infection. Some strains of Lactobacillus 
have even been shown to exert an anti-diabetic effect in animal models [14-16] and humans 
[17]. 
1.2 LACTOBACILLUS AS A DELIVERY SYSTEM 
Bioengineering of the probiotic Lactobacillus strains could potentially combine the 
colonizing ability and probiotic effect with an engineered therapeutic function. Selected 
probiotic Lactobacillus strains could colonize the GI tract for weeks [18]. Orally administered 
engineered Lactobacillus strains could survive the gastrointestinal passage and transiently 
colonize the GI tract where they could constitutively produce therapeutic molecules, reducing 
their exposure to gastric acid, bile and digestive enzymes. This would provide a continuous 
supply of biologically active peptides, which, could directly interact with receptors in the gut 
or be absorbed through the intestinal epithelium [19].  
1.2.1 Lactobacillus expression systems 
Therapeutic peptides expressed in Lactobacillus are normally designed to be anchored on the 
cell wall surface or secreted into the culture medium. Therefore, a strong promoter and a 
functional signal peptide fused to the peptide-encoding genes are needed for their expression. 
To maximize the expression level, inducible promoters have been employed in order to 
reduce the growth pressure caused by “toxic” peptides. Most popular systems, relying on 
quorum sensing mechanism to drive gene expression, include the NICE (nisin-controlled 
gene expression) system from Lactococcus lactis and the sakacin-based expression system 
from Lactobacillus sakei [20, 21]. However, inducible systems are less suitable for in situ 
production in the GI tract, and a constitutive active promoter enabling stable expression level 
is required for such applications [22]. Signal peptides can also affect protein expression and 
secretion, and many studies have explored different signal peptides for protein production in 
Lactobacillus [23-25]. The prediction of the signal peptide cleavage site is possible [26], but 
there are no specific rules in the selection of signal peptide as it may depend on the fused 
peptide and the Lactobacillus strains [23, 27].  
Besides the secreted peptides, cell wall anchoring can be achieved by fusing the peptide gene 
with a selected protein binding domain from lactobacilli. The peptide could attach to the cell 
surface either covalently via the LPXTG motif or noncovalently through hydrophobic or 
ionic interactions [28, 29]. Covalent anchoring is mediated through a sortase-dependent C-
terminal anchoring domain which contains a cleavage site, the conserved LPXTG motif, 
located in the C-terminal region of the protein [28]. After secretion, the sortase cleaves the 
LPXTG motif between the threonine and glycine and links the protein covalently to the cell 
wall peptidoglycan [29].  
The expression system developed in our group is regulated by a constitutive promoter of the 
aggregation promoting factor (apf) gene from Lactobacillus crispatus M247 and secretion is 
mediated by the signal peptide of the apf gene. For covalent surface anchoring on the cell 
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wall, the gene of interest is fused to the sequence encoding the last 231 amino acids of the 
proteinase P surface protein (PrtP) (containing a C-terminal LPXTG motif) from L. paracasei 
BL23 [30]. Most expression systems in lactobacilli are plasmid-based vectors that contain 
antibiotic markers. For therapeutic use in vivo, food-grade chromosomal integrated 
expression systems which are antibiotic-free have been developed [30-33]. The integrative 
expression systems showed a stable expression level, however, a reduced expression level 
might be observed due to that each bacterium contains one copy of the chromosomally 
integrated gene but multi-copies of the plasmid carried gene. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Expression cassettes of the pAF plasmid series for secreted and surface display of 
protein in lactobacilli. SP, signal peptide; RBS, ribosomal binding site; C-ter, C-terminal part 
of APF gene; translation stop codon (indicated with an arrowhead) and the transcription 
terminator (indicated with a lollipop). Cell surface of lactobacilli with a schematic 
representation of cell-wall associated proteins (the figure was adapted from [28]). The 
proteins are attached covalently to the cell wall through a LPXTG sorting motif. 
1.2.2 Delivery of therapeutic molecules 
Lactic acid bacteria, especially Lactococcus lactis and Lactobacillus, have become popular 
vehicles to deliver prophylactic and therapeutic molecules to the mucosa. In the beginning, 
the work mainly focused on delivering antigens for mucosal vaccination since they can elicit 
antigen-specific secretory IgA responses at the mucosal surface [1]. The initial work on 
delivery of therapeutic molecules was carried out in L. lactis [34], a strain widely used in the 
dairy industry and with high transformation efficiency. One of the most promising studies 
was the use of IL-10-secreting L. lactis to treat inflammatory bowel disease (IBD) in mouse 
models [35] and humans [36]. Lactobacilli are natural inhabitants of the human GI tract, and 
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transient colonization of the gut might provide prolonged delivery of peptides, an advantage 
compared to L. lactis.  
Lactobacilli have been used for delivery of passive immunity in the oro-gastrointestinal tract. 
Lactobacilli producing ScFv or VHH antibody fragments were shown to confer protection 
against Streptoccus mutans [37, 38], rotavirus [39, 40], Clostridium difficile toxin B [41] and  
anthrax toxin [42] in rodent models of infection. The antibody fragments produced and 
locally delivered by lactobacilli at the mucosal sites could provide an efficient therapy at a 
low cost [43]. Single chain variable fragment (ScFv) is about 30 kDa and consists of variable 
light (VL) and heavy (VH) regions joined together by a flexible peptide linker. The variable 
domain of llama heavy chain antibody (VHH, or nanobody) is about 15 kDa. VHH is a stable 
single-domain molecule with superior solubility, more acid and heat resistant, and binding 
with similar affinities as conventional antibodies [44]. These traits made it markedly easier to 
express in a functional recombinant form in lactobacilli. Lactobacillus producing surface-
anchored llama VHH antibody fragment (named ARP1) was shown to bind to rotavirus in 
vitro and protect mouse pups against rotavirus-induced diarrhea [39, 40]. Furthermore, 
Lactobacillus producing surface anchored VHH dimer, consisting of ARP1 and ARP3 
antibody fragments directed against VP6 proteins, have an increased therapeutic effect in a 
mouse model of rotavirus infection compared to monovalent VHH [40], probably because 
ARP1 and ARP3 fragments could target multiple epitopes and therefore acting synergistically 
against the virus [45].  
Until now, Lactobacillus have been used to deliver different therapeutic molecules like 
antigens [46-50], antibody fragments [37, 39, 40, 42], cytokines [51-53], enzymes [54] and 
DNA molecules [55]. This thesis focused on delivery of therapeutic peptide (incretin peptide 
and cytokines) by Lactobacillus for treatment of metabolic and immunological disorders.  
1.3 GLUCAGON-LIKE PEPTIDE-1 AND TYPE 2 DIABETES 
1.3.1 Type 2 diabetes 
Type 2 diabetes, formally called non-insulin-dependent diabetes mellitus, is a metabolic 
disorder characterized by high blood glucose levels due to insulin resistance and relative 
insulin deficiency [56]. The World Health Organization estimates that 422 million people in 
the world had diabetes in 2014, of which about 90% was type 2 diabetes. The prevalence of 
diabetes is steadily increasing everywhere, most markedly in the middle-income countries 
[57]. Type 2 diabetes was previously seen only in adults, but it is now increasing rapidly 
among children and adolescents. Treatment of type 2 diabetes involves healthy diet, regular 
physical exercise and oral medication (sulfonylureas, biguanides and thiazolidinediones)[58], 
or insulin therapy. 
1.3.2 Glucagon-like peptide-1 (GLP-1) 
Glucagon-like peptide-1 (GLP-1) is a proglucagon-derived peptide produced by intestinal 
endocrine L cells in response to nutrient ingestion. GLP-1 is an incretin hormone that can 
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stimulate insulin secretion from the pancreas in a glucose-dependent manner, reduce 
glucagon secretion and slow down gastric emptying [59]. Exogenously supplied GLP-1 can 
normalize glucose levels following subcutaneous injections in type 2 diabetic patients [60, 
61]. GLP-1 can also reduce food intake and body weight in obese patients with type 2 
diabetes [62, 63]. Furthermore, GLP-1-induced stimulation of insulin secretion is strictly 
glucose-dependent and does not cause hypoglycemia, a severe side effect of some 
medications presently used for treatment of diabetes [64]. Therefore, GLP-1 and its analogues 
provide an attractive option for treatment of type 2 diabetes.  
GLP-1 is a short peptide that has a highly conserved amino acid sequence in mammals [65]. 
The inactive full-length form of GLP-1 (1-37) is processed into two active circulating forms: 
GLP-1 (7–37) and GLP-1 (7-36) amide, with the latter being the most abundant form found 
in blood. Both forms of GLP-1 are susceptible to dipeptidyl peptidase-4 (DPP-4) -mediated 
degradation and inactivation. GLP-1 has a very short half-life (˂ 2 minutes) and its 
concentration returns to baseline within 90 min after subcutaneous injection [66], making it 
difficult to administer native GLP-1 systemically.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Physiology of GLP-1 secretion and actions in peripheral organs and tissues. GLP-1 
is produced by intestinal L-cells upon nutrients stimulation, and secreted into intestinal small 
blood vessels. GLP-1 stimulates insulin biosynthesis and secretion in the pancreas through 
binding to their distinct receptors on β cells. GLP-1 acts directly on the endocrine pancreas, 
 6 
stomach, heart and brain, whereas actions on muscle and liver are indirect. Figure adapted 
from [67, 68].  
1.3.3 GLP-1 based diabetes therapies 
An alternative treatment involving the GLP-1 pathway is the oral administration of DPP-4 
inhibitors which results in a physiological increase in GLP-1 levels [69, 70]. However, most 
recent research has focused on developing long-acting GLP-1 receptor agonists. GLP-1-Gly8, 
a 31 amino acid peptide of GLP-1 (7–37) with the alanine in position 8 changed into glycine 
(Gly), prolongs the half-life of the peptide by altering the cleavage site for the DPP-4 [71]. 
Approved GLP-1 analogues, including Exenatide (Byetta®) and Liraglutide (Victoza®), can 
prolong the half-life of the peptide to hours [72, 73]. Once-weekly preparation of a GLP-1 
analogue (Albiglutide, Dulaglutide) was also available for therapy [74].  
GLP-1 analogues are currently only administered through the subcutaneous route due to 
degradation by gastrointestinal enzymes [69]. Since GLP-1 is produced predominantly from 
the ileum and colon [75], it is not equally distributed throughout the systemic circulation and 
the highest concentrations are found in the splanchnic blood [76]. Therefore, the current 
subcutaneous injection does not mimic the physiological secretion of GLP-1 [76, 77]. In 
contrast, oral delivery of GLP-1, followed by uptake in the intestinal mucosa, would appear 
more likely to mimic the physiological route while providing a comfortable and convenient 
drug delivery method for patients. A few efforts have previously been made to solve the oral 
delivery problems of GLP-1 by adding functional groups to facilitate absorption [78], by 
PEGylation or encapsulating GLP-1 into nanoparticles to protect the peptides from 
degradation in the GI tract [79-81].  
1.3.4 Advantages of using lactobacilli for delivery of GLP-1 
Engineered Lactobacillus could be used to produce and locally deliver GLP-1 peptide in the 
GI tract, where natural GLP-1 is produced. Lactobacillus could continuously produce 
biologically active GLP-1, reducing their exposure to gastric acid, bile and digestive 
enzymes. 
As one of the best studied probiotic species, some strains of Lactobacillus have been shown 
to exert an anti-diabetic effect in rodents by lowering the blood glucose level [14, 15, 82-84]. 
A recent report also showed that L. reuteri improves incretin and insulin secretion in glucose-
tolerant humans [17]. According to Panwar et al. [16], different Lactobacillus strains, 
including L. rhamnosus GG, L. casei, L. acidophilus, L. plantarum and L. reuteri, have been 
shown to either lower plasma glucose levels or to improve insulin resistance in diabetic 
mouse or rat models. In addition, a recent paper demonstrated that feeding a L. gasseri-
delivered “receptor-inactive” full-length GLP-1 (1-37) in a type 1 diabetic rat model for a 
period of 90 days, could reprogram intestinal epithelial cells into “glucose-responsive insulin-
secreting cells” [85], suggesting that lactobacilli will be suitable candidates for in vivo 
“receptor-active” GLP-1 (7-37) peptide delivery. Bioengineering of the probiotic 
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Lactobacillus strains could potentially combine the colonizing ability and anti-diabetic effect 
of lactobacilli with an engineered GLP-1 therapeutic function. 
1.4 INTERLEUKIN-22 AND GRAFT-VERSUS-HOST DISEASE 
1.4.1 Graft-versus-host disease 
Graft-versus-host disease (GVHD) is a frequent and challenging complication that occurs 
after allogeneic stem cell transplantation in which the newly transplanted immune cells attack 
the tissues of the recipient [86, 87]. Clinical GVHD carries approximately a 50% mortality 
rate, which contributes to most transplant-related morbidity and mortality [88]. GVHD occurs 
in acute and chronic forms. Following hematopoietic stem-cell transplantation, acute GVHD 
develops within 100 days when graft-derived T cells are activated against antigens from the 
recipient, involving mainly the gastrointestinal (GI) tract, the skin, and the liver [89, 90]. 
Acute GVHD of the GI tract is often severe and is a significant cause of transplant-associated 
morbidity [90]. Chronic GVHD describes a more diverse syndrome and normally occurs after 
100 days post transplantation [89]. 
The incidence of acute GVHD ranges between 26% and 32% in recipients of HLA matched 
sibling donor grafts, and from 42% to 52% in recipients of HLA matched unrelated donor 
grafts [91]. The minor histocompatibility antigens, which are small peptides derived from 
polymorphic proteins presented by MHC molecules, are responsible for acute GVHD in these 
HLA matched transplantation [92]. The standard treatment for GVHD is immunosuppressive 
therapy with corticosteroids (such as prednisone), while side effects like increased risk of 
dangerous infections could happen to the patients whose immune systems are already fragile 
after transplantation [93]. Therefore, it is important to further study the pathogenesis of 
GVHD and to develop new therapeutic options. 
1.4.2 Interleukin-22 
Interleukin-22 (IL-22) is a member of the IL-10 family of cytokines, expressed 
predominantly by subsets of innate lymphoid cells (ILCs) and activated T cells, including T 
helper 1 (TH1) cells, TH17 cells and TH22 cells [94, 95]. The mature, secreted form of 
human IL-22 consists of 146 amino acids [95], which shares a 79% amino acid sequence 
identity with mouse IL-22 and a 25% identity with human IL-10. IL-22 can be recognized by 
a heterodimeric receptor complex that consists of two transmembrane subunits: IL-22R1 and 
IL-10R2 [96]. The binding of IL-22 to its receptor activates the JAK/STAT and MAPK 
signaling pathways [97, 98], resulting in gene expression or repression. Since the IL-10R2 is 
shared by five cytokines (IL-10, IL-22, IL-26, IL-28, and IL-29) and is widely expressed in 
most cells [99], the expression of the IL-22R1 determines whether a cell is the target of IL-
22. The lack of expression of IL-22R1 in all immune cells indicates that IL-22 does not 
directly regulate the function of the immune system [100]. The targets of IL-22 are mostly 
non-hematopoietic epithelial and stromal cells in the intestines, lung, liver, pancreas, thymus, 
kidney and skin [94, 95, 101].  
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IL-22 can induce the production of antibacterial peptides from epithelial cells and selected 
chemokines in selected tissues, where it can promote epithelial cell survival and proliferation, 
play an important role in tissue regeneration and protect against damage induced by 
chronic inflammation [94, 102-104]. Additionally, IL-22 can directly stimulate goblet cells to 
secrete mucins, which forms the protecting mucus layer [105]. It can also protect intestinal 
epithelium stem cells from immune-mediated tissue damage and increase their proliferation 
[90]. Local IL-22 gene delivery has been shown to lead to rapid attenuation of intestinal 
inflammation in the colon in a Th2-mediated chronic colitis mouse model [106]. Therefore, 
IL-22 is an attractive and promising target for inflammatory bowel disease (IBD) therapy 
[107]. It might also have beneficial effects in alcoholic liver disease, pancreatic damage and 
GVHD [94].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 IL-22 protects intestinal stem cells from GVHD-mediated tissue damage. Pre-
transplantation conditioning induces IL-23 production from the GI tract. IL-23 stimulates 
ILC3 to produce IL-22, which then protects the intestinal stem cell compartment and 
promotes epithelial recovery from tissue damage. During GVHD, Allogeneic donor T cells 
can eliminate ILC3 and damage the intestinal stem cells. Figure adapted from [90, 94]. 
1.4.3 IL-22 in the treatment of acute GVHD 
Rorγt+ IL-23-responsive innate lymphoid cells, which are present in the gut cryptopatches, 
are a major source of IL-22 [108]. Studies have shown that after allogeneic hematopoietic cell 
transplantation, donor-derived IL-22 aggravates systemic inflammation and increases 
mortality of the recipients [109, 110]. IL-22 deficiency in donor T cells reduced mortality and 
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severity of acute GVHD for the recipients after transplantation [90, 109]. In contrast, IL-22 
deficiency in recipient mice led to increased intestinal GVHD pathology and accelerated 
mortality, indicating that supplement of IL-22 for the recipient may have a therapeutic 
potential in GVHD [90]. Moreover, recombinant mouse IL-22 treatment via intraperitoneal 
injection enhanced the recovery of intestinal stem cells (ISCs), increased epithelial 
regeneration and reduced intestinal pathology and mortality from GVHD in allogeneic bone 
marrow transplanted mice [111, 112].  
Due to the lack of IL-22 receptor on immune cells, IL-22 could potentially be used as a 
relatively safe molecule to treat GVHD without causing any immune-related side effects [94]. 
Administration of recombinant IL-22 to patients with GVHD could support the regeneration 
of epithelial cells without triggering inflammation, which would aggravate the disease. 
Meanwhile, the IL-22 receptor is predominantly expressed on mucosal epithelial cells. An 
oral formulation could thus be a potential way to deliver IL-22 directly to the intestine and 
interact with receptors on the basolateral surface of epithelial cells. 
1.4.4 Advantages of using lactobacilli for delivery of IL-22 
The gut microbiota itself is also known to have an impact on GVHD [113, 114]. Targeting 
anaerobic bacteria and introducing potentially beneficial bacteria could reduce the GVHD 
score [115, 116]. Re-introduction of a mouse commensal, L. johnsonii, alleviates GVHD 
lethality and pathology in a mouse model probably due to the prevention of Enterococcus 
expansion which may otherwise exacerbate GVHD-associated intestinal inflammation [117]. 
Genetically engineered Lactobacillus could be used to deliver IL-22 directly to the intestinal 
GVHD lesions, providing a continuous supply of bioactive IL-22 during the progression of 
the disease. 
1.5 INTERLEUKIN-21, CD40 LIGAND AND IGA DEFICIENCY 
1.5.1 IgA deficiency 
Selective IgA deficiency (IgAD) is defined by a serum IgA level equal to or below 0.07 g/l 
with normal serum IgM and IgG levels in individuals of 4 years of age or older [118]. IgAD 
is the most prevalent primary immunodeficiency diseases (PID) with an estimated frequency 
of 1/600 in the Caucasian population [119]. Most IgAD patients are asymptomatic but 
approximately one third show a significantly increased proneness to recurrent respiratory and 
gastrointestinal infections and an increased prevalence of allergic diseases and autoimmune 
disorders as compared to gender- and age-matched controls [119-122]. IgA is the most 
abundant immunoglobulin class in the body and normally provides immunologic protection 
at the mucosal membranes including the gastrointestinal and respiratory tract [123, 124]. IgA 
plays an important role in mucosal immunity in our defense against extracellular pathogens 
and maintains intestinal homeostasis [123, 125, 126]. IgAD patients have lost the first barrier 
against pathogens and the capability to control the intestinal microbiota; therefore, they are 
susceptible to gastrointestinal infections mainly caused by Giardia lamblia, Campylobacter 
jejuni, and Salmonella spp or lead to overgrowth of commensal bacteria like Clostridium 
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difficile [127, 128]. IgAD is also associated with an increased frequency of celiac disease, 
Crohn’s disease and ulcerative colitis [120]. 
There is no specific treatment for IgAD patients but sinopulmonary or GI tract infections with 
bacteria in IgAD patients are usually treated with antibiotics. Prolonged antibiotic treatment 
may be inevitable and may thus lead to the development of antibiotic-resistant bacteria and 
other adverse physiological side effects [129]. The commonly recommended treatment for 
PID disorders is immunoglobulin G (with only trace amounts of IgA) replacement (IVIG), 
which has been suggested to alleviate symptoms [130]. This treatment is not routinely 
available in many countries due to its high cost. It may also lead to anaphylactic reactions due 
to high titers of anti-IgA antibodies present in some IgAD patients [131, 132].  
IgAD is a heterogeneous disorder and the major barrier in the development of a therapy for 
IgAD is the incomplete understanding of the etiology of this disorder. The phenotypic feature 
of IgAD is a defect in B lymphocyte maturation and subsequent impairment of IgA 
production [133]. Hereditary genetic defects are associated with IgAD where an association 
with both MHC (major histocompatibility complex) and non-MHC genes has been reported 
[119, 134]. The defects in IgA production may result from either a T or a B cell defect, where 
abnormal cytokine production is suggested to play a role [135, 136]. Previous studies have 
shown induction of IgA secretion using different models with different stimulators including 
IL-4, IL-10, IL-21, TGF-β, APRIL and BAFF [125, 137-140]. Among them, the combination 
of CD40L and IL-21 induced the most robust IgA production in peripheral blood 
mononuclear cell (PBMC) from healthy donor, and this effect can be enhanced by IL-4 [140]. 
1.5.2 IL-21 and IL-4 
Human interleukin-21 (IL-21) is a cytokine of the γc family expressed by activated CD4+ T 
cells and NKT cells [141]. IL-21 signals via a heterodimeric receptor complex consisting of 
the IL-21 receptor (IL-21R) and the γ-chain (γc), the latter being shared by IL-2, IL-4, IL-7, 
IL-9, and IL-15 [142, 143]. The expression of IL-21 receptor has been detected on B cells, 
CD4+ T and CD8+ T cells, NK cells, dendritic cells, macrophages and keratinocytes, 
suggesting that IL-21 has a pleiotropic action on a wide range of cell types [144]. IL-21 has 
potent regulatory effect on the immune system including promotion of activation, 
proliferation and differentiation of human B cells [145]. It induces secretion of IgA, IgG, and 
IgM from all subsets of mature B cells [146]. Recently, patients with PID caused by either 
IL-21 or IL-21R gene mutations have been described, indicating a critical role of IL-21 in 
host defense [147-150]. 
Interleukin-4 (IL-4) is a pleiotropic cytokine mainly expressed by Th2 lymphocytes, 
basophils, and mast cells [151, 152]. IL-4 is also a member of the γ-chain receptor cytokine 
family whose receptor complex comprises an IL-4Rα and the common γ-chain shared with 
IL-21 and other cytokines [153]. IL-4Rα has strong homology to IL-21R and previous work 
suggested that both IL-4 and IL-21 hold a conserved capability to bind to IL-21R and IL-4Rα 
[154]. IL-4 was shown to have capacity in B cell growth and differentiation. IL-4 enhances B 
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cell proliferation induced by CD40L [155], induces class-switch recombination (CSR), and 
promotes naïve B cells to switch to IgG1,  IgG4 and IgE production [156-159]. 
The IL-21 induced class switching and plasma cell formation could be modulated or 
complemented by additional cytokines, such as IL-4 [155]. IL-4 increased the amount of IgG 
secreted by naïve B-cell precursors that had been stimulated with IL-21[160, 161]. The IL-21 
alone promoted the induction of IgG3+ B cells, while the combination of IL-21 and IL-4 
favored the generation of IgG1+ switched B cells. 
1.5.3 CD40L 
CD40 ligand (CD40L) is a 261 amino acid transmembrane protein of the tumor necrosis 
factor (TNF) family, expressed as either membrane-bound or soluble form by activated CD4+ 
T cells and B cells [162-164]. It binds to CD40 on antigen-presenting cells (APC), which 
leads to different effects depending on the target cell type. Individuals with CD40 signaling 
defects suffer from a hyper-IgM symptom with little or no IgA production [165]. CD40L 
itself has a minimal effect on antibody production by B cells, but different isotypes of 
antibody can be induced in the presence of different cytokines [166]. Like other TNF family 
members, the membrane-bound homotrimeric CD40L has the highest bioactivity, while the 
soluble dimeric and monomeric forms  have the lowest activity [167].  
Since IL-21 and CD40L signaling is involved in B cell differentiation and antibody class 
switch recombination [165, 168-171], IL-21 could enhance the proliferation of CD40L-
stimulated human B cells. A combination of IL-21 and CD40L induces a strong proliferative 
response in memory B cells [161], and also induces naïve B cells to enter cell division and 
isotype switching rapidly [172]. B cells further differentiate into “plasma-like cells” capable 
of secreting all major immunoglobulin isotypes, predominantly IgG3 and IgG1, and to a lesser 
extent IgA1 [155]. 
1.5.4 Treatment of IgAD with IL-21 and CD40L 
In vitro stimulation with recombinant CD40L and IL-21 induces IgG or IgA production 
efficiently in B cells from healthy donors and, to a lesser extent, IgA deficient patients [140]. 
In combination with IL-2 or IL-4, CD40L and IL-21 can lead to an even stronger IgG and 
IgA production [140]. This suggests that IL-21/CD40L stimulation may be a potential 
therapy for patients with IgA deficiency. Furthermore, since IL-21 and IL-4 are able to bind 
to both IL-21R and IL-4R in an interchangeable manner, a hybrid cytokine which fuses 
elements of IL-21 and IL-4 cytokines might serve as a more efficient therapeutic agent for 
IgAD [154]. 
Intravenously administered human recombinant IL-21 was previously shown to be safe in 
clinical trials to treat metastatic melanoma and renal cell carcinoma [143, 173, 174]. 
However, oral delivery via a suitable carrier could improve the patient compliance or efficacy 
of the cytokines and induce local production of IgA at the mucosal surface where it is most 
needed.  
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1.5.5 Advantages of using lactobacilli for delivery of IL-21 and CD40L 
Lactic acid bacteria, such as Bifidobacterium or Lactobacillus, are able to modulate mucosal 
and systemic immune responses [175-177]. Heat-killed L. rhamnosus GG can enhance 
mucosal IgA production [178], whereas L. johnsonii causes increased IgA production in 
mouse Peyer's patches [179]. The mechanism by which Lactobacillus induce IgA production 
remains unclear, but could be attributed to the surface anchored or secreted proteins [180]. 
The whole bacteria or derived proteins could be taken by transcytosis through the microfold 
cell (M cell) in the Peyer’s patches, or captured by dendritic cells through extension of 
dendrites in the gut lumen. IgA class switching in Peyer’s patches could also be induced 
through an alternative T-cell dependent pathway which relies on the TLR signaling by 
Lactobacillus [168, 181]. 
Lactobacillus, thus appears a good candidate to continuously deliver recombinant IL-21, IL-4 
and CD40L that induce IgA production by B lymphocytes at mucosal sites in IgAD patients. 
 
 
 
 
 
 
 
 
 
Figure 5 Lactobacillus expressing surface anchored CD40L and secreted IL-21 could mimic 
CD4+ T cells to stimulate B cells. 
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2 AIMS 
2.1 GENERAL AIM 
The aim of this thesis was to explore the possibility of using lactobacilli as vectors for 
delivery of peptides in the gastrointestinal tract for therapy against type 2 diabetes and other 
immune-related diseases. 
2.2 SPECIFIC AIMS 
Paper I: To optimize the expression of stabilized GLP-1 analogues in lactobacilli and test the 
bioactivity of the modified lactobacilli in vitro and in the diabetic GK rat model. 
Paper II: To construct Lactobacillus strains for delivery of IL-22 directly to the intestinal 
mucosa as a new therapeutic strategy for acute gastrointestinal GVHD. 
Paper III: To develop a co-expression vector containing two expression cassettes in tandem 
to produce two rotavirus-specific VHH antibody fragments (ARP1 and ARP3) in lactobacilli 
in order to increase therapeutic efficacy. Moreover, this vector can be used to co-express 
other peptides for therapeutic purpose. 
Paper IV: To construct IL-21 and CD40L expressing Lactobacillus strains to induce 
immunoglobulin production in PBMCs from patients with IgAD. 
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3 MATERIALS AND METHODS 
3.1 BACTERIAL STRAINS AND GROWTH CONDITIONS 
L. paracasei BL23 (previously named L. casei ATCC 393 pLZ15-) [182, 183] was a gift from 
Dr. Peter Pouwels (TNO Nutrition and Food Research Institute, Netherlands). Lactobacilli 
were inoculated in liquid MRS medium (Difco, Sparks, MD) from the overnight culture and 
grown statically to OD600 = 1.0 (around 2×108 cfu/ml) or anaerobically on MRS-agar plates at 
37°C. E. coli DH5α (Invitrogen, Carlsbad, CA) was used as a general cloning host and grown 
in LB broth in an orbital shaker or on LB-agar plates at 37°C. Antibiotics were added when 
required: 5 µg/ml erythromycin or chloramphenicol for L. paracasei BL23, and 300 µg/ml 
erythromycin or 100 µg/ml ampicillin for E. coli. 
3.2 SYNTHESIS OF GENES AND PEPTIDES  
All the genes and peptides used in this thesis were synthesized by GenScript Corporation 
(Piscataway, NJ).  
In paper I, the wt (wild type) 5×GLP-1 and trp (trypsin stabilized) 5×GLP-1 genes were 
produced as synthetic genes and codons optimized for expression in L. paracasei. The 
synthetic genes were flanked by an upstream NcoI and a downstream NotI restriction site for 
the subsequent cloning process.  
In paper II, the mouse IL-22 gene was synthesized with codons optimized for expression in L. 
paracasei. The synthetic genes flanked by an upstream BamHI and a downstream SacI 
restriction site for subsequent cloning.  
In paper III, synthetic genes coding for human IL-21, hybrid IL-21/4 and CD40L were 
synthesized. The sequence of IL-21 and CD40L was codon optimized according to the codon 
usage of L. paracasei. The synthetic IL-21 and IL-21/4 genes were flanked by an upstream 
BamHI and a downstream SacI restriction site for subsequent cloning. 
In paper IV, the genes encoding the ARP3, VSV-G-tag, prtP and apf transcription terminator 
was synthesized. The ARP3 and prtP genes were codon optimized to reduce recombination 
between the two cassettes cloned in tandem. The synthetic genes were flanked by an 
upstream EcoRI and a downstream PvuI restriction site while the VSV-G-tag was flanked by 
MluI and NheI for subsequent cloning. 
In paper I, the GLP-1 peptide (98.3% purity, 31 amino acids) and its analogue GLP-1-Gly8 
(97.5% purity, 31 amino acids) were produced synthetically by GenScript Corporation. 
3.3 CLONING IN LACTOBACILLUS 
Four shuttle expression plasmids were used for expression of therapeutic peptides. The 
expression vectors pAFβ100 and pAF100 mediate secretion, while the pAFβ900 and pAF900 
mediate surface anchoring of the peptide. The detailed description of pAF and pAFβ plasmid 
series construction can be found in our previous work [30] and paper II. In most cases, 
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synthesized genes were digested with specific pairs of restriction enzymes and ligated into the 
expression vectors excised using the same restriction enzymes. Meanwhile, assembly PCR 
was also employed to facilitate changes of different parts of the expression cassettes 
(promoters, signal peptides or affinity tags). Details of the construction process can be found 
in the respective paper. 
The expression plasmids were first transformed into E. coli DH5α by electroporation and the 
expression cassettes were verified by Sanger sequencing (Eurofins Genomics, Germany). The 
plasmids were subsequently transformed into L. paracasei BL23 [37, 184] by electroporation 
as previously described [37]. 
3.4 EXPRESSION ANALYSIS 
3.4.1 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was used to quantify the expression level of IL-22 from lactobacilli and the secretion 
level of IL-10 from Colo205 cell line in paper II.  
Flat-bottom 96 well plates (EIA/RIA, Costar) were coated with 1 µg/ml goat anti-mouse IL-
22 antibody (R & D Systems) or goat anti-human IL-10 antibody (Sigma) overnight at 4°C, 
and then followed by blocking with 1% BSA in PBST (PBS containing 0.05% Tween 20) for 
two hours at room temperature. Serial dilutions of the Lactobacillus supernatant (1/10 to 
1/1280) from Lp pAFβ100-IL22 or Colo 205 cell culture supernatant were added and 
incubated at room temperature for 2 h. Recombinant mouse IL-22 (R & D Systems) or 
human IL-10 (BD Pharmingen) was used to create a standard curve at concentrations of 500 
ng/ml to 244 pg/ml. Plates were washed with PBST and a biotinylated goat anti-mouse IL-22 
antibody (0.2 µg/ml, R & D Systems) or biotinylated goat anti-human IL-10 antibody (1 
µg/ml, R & D Systems) was added and incubated at room temperature for 1 h. Plates were 
subsequently washed with PBST and incubated for one hour with streptavidin-alkaline 
phosphatase (1/1000 dilution, BD Pharmingen) at room temperature for detection. 
Diethanolamine buffer (1 M, pH=10.0) containing 1 mg/ml of pNPP (Sigma-Aldrich) was 
added to the wells. After 20 min incubation, absorbance was read at 405 nm in a Varioskan 
Flash microplate reader (Thermo Electron Corporation). 
ELISA was also used to evaluate the binding of antibody fragments to rotavirus in paper III. 
The protocol was slightly modified as follows: ELISA plates were coated with anti-rotavirus 
HBC antibodies (5 µg/ml) for 2 h, prior coating with rotaviruses overnight at 4°C. ARP1 was 
detected using a mouse anti-E-tag antibody (1/2000) followed by an alkaline phosphatase 
conjugated rabbit anti-mouse antibody (Dako, 1/1000), and ARP3 was detected using a 
biotinylated anti-V5-tag antibody followed by alkaline phosphatase conjugated streptavidin 
(Becton Dickinson, 1/1000).   
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3.4.2 Western Blot  
Western blot was used to detect the expression of peptides and cytokines from Lactobacillus. 
The antibodies used in this thesis are listed in Table 1.  
Table 1 Antibodies used in the Western blot.  
 Primary antibody Secondary antibody Target 
Paper I 
Mouse monoclonal anti-
Glucagon-like peptide-1 (Mid-
molecule specific, BioPorto), 0.5 
µg/ml 
HRP conjugated goat anti-
mouse antibody (Dako A/S, 
Glostrup, Denmark), 1/1000 
GLP-1 
Paper II 
Biotinylated goat anti-mouse IL-
22 antibody (R & D Systems), 
0.2 µg/ml 
HRP conjugated streptavidin 
(BD Pharmingen, USA), 
1/2000 
IL-22 
Paper III 
Mouse monoclonal anti-E-tag 
antibody (Phadia AB, Uppsala, 
Sweden), 1 µg/ml 
HRP conjugated goat anti-
mouse antibody (Dako A/S, 
Glostrup, Denmark), 1/1000 
E-tag 
(ARP1) 
Biotinylated mouse monoclonal 
anti-V5-tag antibody (AbD 
Serotec, Kidlington, UK), 1/5000 
HRP conjugated streptavidin 
(BD Pharmingen, USA), 
1/2000 
V5-tag 
(ARP3) 
Paper IV 
Biotinylated rabbit anti-mouse 
IL-21 antibody (R & D Systems), 
0.2 µg/ml 
HRP conjugated streptavidin 
(BD Pharmingen, USA), 
1/2000 
IL-21 
Mouse monoclonal anti-E-tag 
antibody (Phadia, AB, Uppsala, 
Sweden), 1 µg/ml 
HRP conjugated goat anti-
mouse antibody (Dako A/S, 
Glostrup, Denmark), 1/1000 
E-tag 
(CD40L) 
The bacterial cultures were centrifuged when OD600 reached 1.0. The supernatant was filter-
sterilized using a 0.2 µm filter and the pH was adjusted to 7.0. Then, 100 µl of supernatant 
was mixed with an equal volume of 2×Laemmli buffer (Bio-Rad) and boiled for 5 min. The 
bacterial pellets from 1 ml culture were washed twice with PBS followed by resuspension in 
100 µl 2×Laemmli sample buffer and boiled for 10 min. The boiled samples were centrifuged 
at 16100×g to remove cell debris and the supernatant containing the soluble proteins was 
retained as a cell extract sample. Ten ng of the commercial recombinant peptide (positive 
control) and 20 µl of the supernatant or the cell extract were run on a 12% SDS-PAGE gel. 
The proteins were then transferred onto a nitrocellulose membrane (Hybond-ECL, GE 
Healthcare, UK). After overnight blocking with 5% skim milk in PBST, the membrane was 
incubated with primary antibody for 2 h, followed by washing 4 times with PBST, and then 
incubated with secondary antibody for 1 h. The signal was detected by chemiluminescence 
using the ECL Western blotting detection system (GE Healthcare). 
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Furthermore, the amount of IL-22 produced in the supernatant of Lactobacillus (Lp 
pAFβ100-IL22) cultures was quantified by Western blot densitometry and compared to 
commercial recombinant IL-22 protein (Paper II). In paper III, the amount of ARP1 and 
ARP3 fragments produced in the supernatant and cell extract of Lactobacillus cultures was 
also quantified by Western blot densitometry as compared to known concentration of affinity 
column purified ARP1 and ARP3 proteins. 
3.4.3 Flow cytometry 
Cell wall display of peptides and cytokines on the surface of Lactobacillus was confirmed by 
flow cytometric analysis.  
Table 2 Antibodies used in the flow cytometry. 
 Primary antibody Secondary antibody Target 
Paper I 
Mouse monoclonal anti-
Glucagon-like peptide-1 (Mid-
molecule specific, BioPorto), 
1/200 
FITC-conjugated goat anti-
mouse antibody (Jackson 
Immunoresearch Lab., West 
Grove, USA), 1/200 
GLP-1 
Paper II 
Biotinylated goat anti-mouse IL-
22 antibody (R & D Systems), 1 
µg/ml 
FITC-conjugated goat anti-
mouse antibody (Jackson 
Immunoresearch Lab., West 
Grove, USA), 1/200 
IL-22 
Paper III 
Mouse monoclonal anti-E-tag 
antibody (Phadia AB, Uppsala, 
Sweden), 1/100 
FITC-conjugated goat anti-
mouse antibody (Jackson 
Immunoresearch Lab., West 
Grove, USA), 1/200 
E-tag 
(ARP1) 
Biotinylated mouse monoclonal 
anti-V5-tag antibody (AbD 
Serotec, Kidlington, UK), 1/400 
FITC conjugated streptavidin 
(Biolegend, San Diego, CA), 
1/200 
V5-tag 
(ARP3) 
Paper IV 
Mouse monoclonal anti-E-tag 
antibody (Phadia, AB, Uppsala, 
Sweden), 1 µg/ml 
FITC-conjugated goat anti-
mouse antibody (Jackson 
Immunoresearch Lab., West 
Grove, USA), 1/200 
E-tag 
(CD40L) 
Fifty µl of Lactobacillus cultures grown to an OD600 of 1.0 were pelleted by centrifugation 
and washed twice in PBS. Bacteria were incubated with a primary antibody for 30 min on ice. 
After two PBS washes, the cells were incubated with a secondary antibody (or streptavidin) 
on ice for 30 min in the dark. The primary and secondary antibodies were diluted in PBS 
containing 1% BSA. After washing three times with PBS, samples were resuspended and 
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fixed in 400 µl 2% paraformaldehyde and analyzed using a FACS Calibur machine (Becton 
Dickinson, Franklin Lakes, NJ). All results were further analyzed by the FlowJo™ software. 
3.5 PLASMID LOSS ASSAY (PAPER II AND IV) 
To evaluate whether the non-stained population observed in flow cytometry of the anchored 
cytokine expressing lactobacilli is due to the plasmid loss, an assay was carried out to test the 
plasmid loss of cytokine expressing lactobacilli during growth under antibiotic pressure. The 
bacteria were cultured under normal conditions with antibiotic supplemented to an OD600 
=1.0, followed by dilution of 106 fold in MRS medium, and then plated on MRS plates with 
or without specific antibiotic. After two days growth anaerobically, the colonies on each 
plates were counted. The experiment was performed in duplicate.   
3.6 PROTEIN PURIFICATION 
In paper I, wt 5×GLP-1 and trp 5×GLP-1 were expressed in E. coli with His-tag and purified 
to approximately 85% purity by GenScript (Piscataway, NJ). The Lactobacillus-produced Lp 
wt 5×GLP-1 and Lp trp 5×GLP-1 were purified from the culture supernatant of lactobacilli 
with anti-E-tag monoclonal antibodies coupled to an NHS-HiTrap sepharose column (GE-
healthcare) according to the manufacturer’s instructions. The eluate was concentrated to a 
volume of 0.5 ml using an Amicon Ultra-4 3K centrifugal filter (Millipore, Billerica, USA). 
The purity of purified 5×GLP-1 was verified on SDS-PAGE and the concentration was 
determined by the Micro BCA Protein Assay Kit (Pierce, Rockford, USA) as compared to 
known concentration of E. coli purified 5×GLP-1.  
In paper III, the ARP1 and ARP3 were also purified from supernatant of Lactobacillus 
pAF1200 using NHS-HiTrap sepharose column (GE-healthcare) coupled to anti-E-tag or 
anti-V5 monoclonal antibodies according to the manufacturer’s instructions.  
3.7 IN VITRO MODEL 
3.7.1 Insulinotropic activity on HIT-T15 cells (paper I) 
The hamster β-cell line HIT-T15 (ATCC CRL-1777) is a popular in vitro model to study 
insulinotropic drugs [185]. HIT-T15 cells (passages 81–82) were maintained in RPMI-1640 
(Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% Penicillin/Streptomycin 
(Invitrogen AB). The cells were subcultured in 6-well plates at a density of 1×105 cells/well, 
and then cultured for 5 days before use in the experiment.  
The cells were incubated twice with 2 ml Krebs-Ringer Buffer (KRB) containing 0.1% BSA 
at 37°C for 30 min, rinsed once with 2 ml KRB containing 0.1% BSA and incubated with 1 
ml KRB buffer (either without glucose or with 5.6 mM glucose) containing digested 
pentameric GLP-1 purified from Lactobacillus or E. coli for 60 min at 37°C. 100 nM of 
synthesized GLP-1-Gly8 peptide was used as a positive control. Following incubation, the 
cell-free supernatants were subjected to insulin quantification using a rat insulin ELISA kit 
(Mercodia AB). 
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3.7.2 IL-22 biological activity assay (paper II) 
The bioactivity of Lactobacillus produced mouse IL-22 was measured by its ability to 
stimulate IL-10 secretion in the human colon cancer cell line Colo 205 [186]. Colo 205 cells 
were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% 
Penicillin/Streptomycin. Cells grew loosely attached or in suspension in flasks till 
confluency, they were then seeded in 6-well plates at a density of 1×106 cells/well.  
Two strains of Lactobacillus, Lp pAFβ100-IL22 secreting IL-22 and Lp pAFβ900-IL22 
producing surface anchored IL-22, were tested. The wild type L. paracasei BL23 strain was 
used as a negative control. The supernatants of Lp pAFβ100-IL22 and wild type 
Lactobacillus from 10 ml MRS culture were harvested at OD600 =0.8 and adjusted to pH=7.0 
before use. The bacterial pellets of Lp pAFβ900-IL22 and wild type Lactobacillus were 
washed twice with PBS, resuspended in PBS and treated with UV light using a cross linker 
(for 2 min at 120 millijoules/cm2) to kill the bacteria before use. Recombinant mouse IL-22 
(R & D Systems), dilutions of bacterial culture supernatant or killed bacteria was added to 
Colo 205 cells in a total volume of 2 ml. The cells were incubated at 37°C for 22 hours, and 
then the supernatant was collected and tested for human IL-10 concentrations by ELISA. 
3.7.3 PBMCs stimulation and enzyme-linked immunospot (ELISPOT) assay 
(paper III) 
3.7.3.1 PBMCs separation  
Heparinized peripheral venous blood was obtained from healthy blood donors and IgAD 
patients. PBMCs were isolated and cryopreserved as described by Kreher et al. [187]. 
Thawed PBMCs were washed twice with IMDM (Gibco) and cultured in IMDM with 
GlutaMAX™ supplement, 1% penicillin-streptomycin, and 10% heat-inactivated fetal bovine 
serum (Gibco) at 37°C in the presence of 5% CO2.  
3.7.3.2 PBMCs stimulation  
To measure the biological activity of Lactobacillus produced IL-21, IL-21/4 and CD40L, the 
strains were grown in MRS to an OD600=1.0 and centrifuged for 10 min. The bacterial pellets 
were washed twice in PBS while the culture supernatant was filter-sterilized and pH adjusted 
to 7.0. The supernatant was concentrated 10 times using Amicon Ultra-4 10K centrifugal 
filter (Millipore). PBMCs (3×106) were co-cultured for 6 days with a mixture of either: 1) 
concentrated culture supernatant of Lactobacillus secreting IL-21 or IL-21/4 with 20 ng/mL 
MegaCD40L (Enzo Life Sciences) or 2) bacteria from Lp pAF900-CD40L with 10 ng/µl 
human IL-21 (R & D Systems). The supernatant or pellet of the non-expressor L. paracasei 
BL23 was used as negative controls. The positive control consist of MegaCD40L (20 ng/mL) 
and recombinant IL-21 (50 ng/ml) only. 
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3.7.3.3 Enzyme-linked immunospot (ELISPOT) assay 
MultiScreenHTS filter plates (EMD Millipore) were prewet with 20% ethanol, rinsed 3 times 
with sterile PBS, and coated with either polyclonal rabbit anti–human IgA or IgG antibody 
(10 µg/mL, SouthernBiotech) overnight at 4°C. After washing, plates were blocked with 
IMDM containing 10% fetal bovine serum and 1% bovine serum albumin (BSA, Sigma-
Aldrich) for 2 h. On day 6 of stimulation, PBMCs were washed once with culture medium 
and plated at 1×105 cells/well in ELISPOT plates. The plates were incubated for 48 h at 
37°C in the presence of 5% CO2. Thereafter, the plates were washed 6 times by PBS 
containing 0.01% Tween20 (PBST). The detection antibodies, goat anti–human IgG-
alkaline phosphatase and goat anti–human IgA-alkaline phosphatase (SouthernBiotech), 
were diluted in PBS containing 0.5% BSA at 2 µg/ml, and then 60 µl were added to each 
well. After incubation overnight at 4°C, the plates were washed 6 times with PBST. Spot 
development was carried out using the BCIP/NBT Liquid Substrate System (Sigma-Aldrich) 
and then analyzed on the AID EliSpot Reader using AID reader software (AID GmbH, 
Germany).  
3.8 ANIMAL MODEL (PAPER I) 
Goto-Kakizaki (GK) rats, which is a spontaneous non-obese type 2 diabetes model [188], 
were used for testing the activity of synthesized 5×GLP-1 peptide and Lactobacillus or E. 
coli produced 5×GLP-1. GK rats were housed at 22°C with an alternating 12-hour light-dark 
cycle and access to standard pellet diet (B&K Universal) and water.  
For testing the activity of monomeric synthetic GLP-1-Gly8 peptide, GLP-1-Gly8 was given 
subcutaneously to GK rats at a dose of 0.5–1.5 mg/kg body weight. For testing the activity of 
E. coli produced 5×GLP-1 peptide, rats were cannulated with a catheter inserted into the 
small intestine to avoid the peptide being digested before reaching the intestine. For testing 
the Lactobacillus producing pentameric GLP-1, rats were gavaged with two doses of 
Lactobacillus strains (1010 cfu) daily.  
3.8.1 Intraperitoneal glucose tolerance test (IPGTT) 
An IPGTT was used to measure the clearance of glucose from the GK rat after 
administration of GLP-1 peptide or Lactobacillus expressing 5×GLP-1. GK rats were fasted 
overnight before the experiment. A solution of glucose (2 g/kg of body weight) was 
administered by intraperitoneal injection, followed by blood glucose measurement at 
different time-points during the subsequent 3 hours. Blood was obtained by the tail-prick 
method and measured using a glucometer. 
3.8.2 Oral administration of lactobacilli  
To test the anti-diabetic effect of 5×GLP-1 expressing Lactobacillus, each group of GK rats 
(n = 6) was given either PBS or Lactobacillus strains (KKA101, KKA394 or KKA403) by 
gavage continuously for seven days. The lactobacilli were grown to the logarithmic phase, 
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pelleted by centrifugation, washed twice with PBS and finally resuspended in PBS at 1010 
cfu/ml. One ml of either PBS or Lactobacillus suspension was given to each rat. 
Non-fasting blood glucose levels were measured by tail-prick method every morning. At 
the end of the experiment (the morning of day 7 after whole night fasting), rats were given 
the last gavage of lactobacilli and then subjected to an IPGTT with 2 g glucose/kg body 
weight 15 min later. The serum sample was taken from the tail vein at days 0, 6 and 13. The 
body weight of the rats was monitored every day during the 14-day experimental period. 
3.9 STATISTICS 
Two-way repeated ANOVA followed by the Student-Bonferroni multiple-range test was used 
to estimate the significance of differences for glycaemia between groups during IPGTT and 
the Lactobacillus treatment period. One-way ANOVA followed by the Student-Bonferroni 
multiple-range test was used to estimate the significance of differences between groups for 
area under the curve of blood glucose levels during IPGTT. Difference in insulinotropic 
effect between purified peptides from E. coli and Lactobacillus was analyzed by the unpaired 
t-test with Welch’s correction. Differences were considered statistically significant if p<0.05. 
Data were analyzed using Excel (Microsoft Corp.) and GraphPad Prism v6.0 (GraphPad 
Software). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
This paper describes our first attempt to deliver a therapeutic peptide using our Lactobacillus 
expression system directly in the gastrointestinal tract. The incretin peptide GLP-1 was 
chosen due to some reasons: 1) GLP-1 is naturally released from the L-cells in the ileum and 
colon, while oral delivery of peptides followed by uptake through the intestine would more 
likely mimic physiological GLP-1 secretion than the current subcutaneous injection routine. 
2) It has been shown that orally administered GLP-1 is rapidly absorbed and markedly affects 
the glucose level in healthy human subjects [76] when a large dose (2 mg) is given. 3) 
Lactobacillus strains can colonize the gastrointestinal tract temporarily, providing a 
continuous supply of GLP-1 peptide, which would facilitate absorption through epithelial 
cells. 
4.1.1 From GLP-1 to 5×GLP-1 
Based on a previous report [71] and the activity of the peptide on the isolated rats’ islet and in 
subcutaneously injected GK rats, GLP-1-Gly8 was chosen to be expressed by Lactobacillus. 
Previous reports have also shown that the intact N-terminal histidine of the mature GLP-1 
peptide is important for its insulinotropic effect [189, 190]. However, the N-terminus of 
Lactobacillus naturally secreted proteins rarely start with a histidine [25]. Since the protein 
secretion is strongly determined by the signal peptide, 8 different signal peptides from 
Lactobacillus naturally secreted proteins were selected for fusion to the GLP-1-Gly8 gene 
based on a prediction of cleavage sites by SignalP [25, 26]. However, none of them led to the 
secretion of GLP-1-Gly8 with a correct N-terminal cleavage. This failure led us to design a 
pentameric form of GLP-1 (5×GLP-1) which consists of five consecutive GLP-1-Gly8 
monomers in tandem. Fourteen extra amino acids from the APF fusion partner were left on 
the N-terminal of 5×GLP-1 to facilitate a good cleavage and secretion of this peptide, and a 
tag was added to facilitate purification or detection. Most importantly, the 5×GLP-1 was 
expected to be digested by the intestinal trypsin into five active monomers of GLP-1 (starting 
with a histidine) when it is released into the intestine. A wildtype pentameric GLP-1 (wt 
5×GLP-1) and a trypsin-stabilized version of the pentamer (trp 5×GLP-1, which includes two 
mutations in the GLP-1-Gly8 monomers to stabilize it against tryptic digestion within the 
monomer) were constructed. We believed that this design would guarantee the intact N-
terminal of GLP-1-Gly8 delivered into the GI tract, while also increase the amount of 
functional peptide being delivered.  
4.1.2 5×GLP-1 analogues are bioactive 
The 5×GLP-1 analogues were both successfully expressed in a secreted form and anchored 
on the surface of lactobacilli. The trypsin digested 5×GLP-1 produced both by Lactobacillus 
and E. coli showed a glucose dependent insulinotropic effect on the pancreatic β-cell line.  
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This in vitro result proved that 5×GLP-1 expressed from Lactobacillus and E. coli have a 
similar bioactivity. This result was of importance for the following in vivo experiment, since 
we cannot purify a large amount of 5×GLP-1 from lactobacilli but the purification from E. 
coli is rather cheap and efficient. 5×GLP-1 was purified from E. coli, and delivered by 
intestinal intubation to GK rats, resulting in a significant improvement of glycemic control 
demonstrated by IPGTT. 
4.1.3 Oral delivery of 5×GLP-1 by Lactobacillus to the diabetic rats 
When the 5×GLP-1 expressing lactobacilli were given by oral gavage twice daily to GK rats 
for 7 days, only the rats receiving non-expressing lactobacilli (negative control) showed a 
significant decrease in blood glucose as compared to the PBS control. The anchored trp 
5×GLP-1 showed a similar trend to lower the blood glucose level, but not to a statistically 
significant degree. Similar results were observed in a repeat of this experiment with an 
extended 14-days treatment.  
The non-expressor L. paracasei BL23 could significantly lower the blood glucose level, 
which can be explained by the anti-diabetic effect of lactobacilli (either lower plasma glucose 
levels or improve insulin resistance in diabetic animal models) reported recently by many 
groups [16, 17, 82-84].  
The limited amount of GLP-1 delivered by lactobacilli might be the main reason that no 
significant difference was observed compared to the non-expressor lactobacilli. The 
theoretical maximum amount of GLP-1 given by the anchored strain is 1.5 µg GLP-1 per rat 
[30], which is significantly lower than the amount of purified E. coli 5×GLP-1 (around 1 
mg/rat) that was given through the intestinal catheter.  
Secondly, some lactobacilli might lose their ability to express 5×GLP-1 when delivered in the 
intestine since the antibiotic pressure which maintains the plasmid is absent in vivo. The 
plasmid loss rate was approximately 40% for the anchored trp 5×GLP-1 strains and 65% for 
the secreted 5×GLP-1 strains when passing through the GI tract of the GK rats. This problem 
may be solved by integrating the 5×GLP-1 gene into the Lactobacillus chromosome and 
thereby stabilizing its expression. 
Thirdly, it is worth noting that the secreted and surface anchored strains behave differently in 
the lactobacilli feeding experiment as only the trp 5×GLP-1-anchored lactobacilli (and non-
expressor lactobacilli) demonstrated a trend towards daily blood glucose level reduction. In 
our previous study involving delivery of antibody fragments, both secreted and surface 
anchored constructs were used, but the majority of study showed that the anchored display is 
more effective in reducing infection than the secreted one in vivo [37-40, 191]. In this study, 
the anchored lactobacilli act like beads already loaded with 5×GLP-1 peptides that can be 
immediately proteolytically released upon contact with trypsin in the intestine, while on the 
contrary, the secreted lactobacilli depend on the secretion of the peptide in situ in the 
intestinal tract. Since the non-expressor lactobacilli is more effective in reducing daily 
glucose level, there might be an undefined mechanism whereby surface molecules involved 
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in the anti-diabetic effect of lactobacilli had been hindered in the secreting strain, but not in 
the surface anchored strain. However, we would normally expect that surface anchoring 
influences more the surface structures than the secreted construct. This interesting 
observation might lead to future studies investigating the anti-diabetic effect of Lactobacillus 
strains. 
Finally, we did consider the expression level from the beginning by designing a pentameric 
GLP-1 to increase the amount of peptide that each Lactobacillus could deliver. We also 
expected a higher local concentration of 5×GLP-1 in the intestine when delivered by 
Lactobacillus. Even so, further work is still needed to increase the expression level of GLP-1 
by lactobacilli in order to see a significant insulinotropic effect in vivo. 
4.2 PAPER II 
IL-22 plays a prominent role in epithelial regeneration and dampening of 
chronic inflammatory responses by protecting intestinal stem cells from immune-mediated 
tissue damage. IL-22 is referred to as a cytokine that has a therapeutic potential in GVHD 
[192], which is a frequent complication following allogeneic stem cell transplantation. Here 
we chose to express mouse IL-22 in lactobacilli both as a secreted product and covalently 
anchored on the surface of lactobacilli. If the bioactivity of lactobacilli produced IL-22 can be 
proved, later it could be used for delivery of IL-22 directly to the intestinal mucosa as a new 
therapeutic strategy for GVHD.  
4.2.1 Expression and display of IL-22 
To express the mouse cytokine IL-22, a new expression vector pAFβ, which is very similar to 
the pAF series vector, was constructed. The pAFβ series, based on the pIAβ8 shuttle plasmid, 
has a different antibiotic marker for selection (chloramphenicol instead of erythromycin). 
Furthermore, the expressed IL-22 has only 6 extra-amino acids on the N-terminus following 
signal peptide cleavage compared to 13 extra-amino acids if the pAF series would be used. 
We were not sure if this change would lead to a better expression and secretion, but it would 
make the expressed IL-22 more similar to the original peptide, therefore maybe resulting in a 
better bioactivity.  
Successful expression of mouse IL-22 was demonstrated by Western blot and flow 
cytometry. When grown in MRS medium, Lactobacillus acidifies the growth medium from 
6.3 to pH 4.5. Since IL-22 is a member of the IL-10 family of cytokines and IL-10 is highly 
sensitive to low pH less than 5.5 [193], we tested the sensitivity of IL-22 to low pH caused by 
lactic acid produced by Lactobacillus. Slight increase (approximately 0.3-fold) in IL-22 
concentration was observed when the lactobacilli expressing IL-22 were grown in pH 
adjusted medium. However, these results are not significant enough to determine if the 
slightly reduced IL-22 level in pH non-adjusted MRS is due to the sensitivity of IL-22 to low 
pH. It is however certain that the effect of pH on IL-22 production is not as important as for 
IL-10. 
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The display of mouse IL-22 on the surface of Lactobacillus strain was demonstrated by flow 
cytometry but only in a small proportion (20%) of the lactobacilli. A non-displayed 
population has been previously observed using flow cytometry in our anchored 5×GLP-1 
expressing lactobacilli (˂24%) but not to such a high level (80%). A large population of non-
stained lactobacilli was more recently observed when we expressed cytokines (see paper IV). 
It is worth noting that these strains were also growing very slow in the liquid MRS medium 
with antibiotics. The plasmid loss assay revealed that 60% of the secreted IL-22 strain and 
75% of the anchored IL-22 strain lost their plasmid during growth even under antibiotic 
pressure, which is corresponding to the flow cytometric results of IL-22 surface display. We 
may speculate that the slow growth of these strains could be due to survival pressure caused 
by expressing the cytokine which lead to plasmid loss.  
4.2.2 Bioactivity of IL-22 
The Lactobacillus secreted and anchored mouse IL-22 were both proven to be biologically 
active, as determined by their ability to induce IL-10 secretion in an in vitro model (Colo 205 
human colon cancer cell line). Our results suggest that IL-22 expressing lactobacilli may 
potentially be a useful mucosal therapeutic agent for the treatment of GVHD, provided that 
higher expression levels can be achieved. 
The dose of IL-22 that reduces intestinal pathology and mortality from graft-versus-host 
disease was shown to be 1.5×1014 molecules when using intraperitoneale injection. To be able 
to test our Lactobacillus strains in the GVHD mice model in future, the current amount of IL-
22 peptide that lactobacilli could delivered is probably still not sufficient (maximum 2.2×1013 
molecules) in order to reach the Intestinal stem cell compartment at the bottom of the crypt of 
the intestinal epithelium. Furthermore, plasmid loss was observed during growth in the 
culture medium and it is expected that such plasmid loss will increase in the absence of 
antibiotic selective pressure in vivo. Further experiments should be performed to improve the 
IL-22 delivery by integrating the expression cassette into the Lactobacillus chromosome and 
thereby stabilizing its expression. 
4.3 PAPER III 
Anti-rotavirus specific VHH fragments, denoted as ARP1 and ARP3, derived from a rhesus 
rotavirus immunized library from llamas, were previously expressed as monomers as well as 
homo- and hetero- dimers on the cell surface of lactobacilli [39, 40]. In this paper, we 
developed co-expression vectors containing two expression cassettes in tandem for 
expression of two different VHH antibody fragments against rotavirus in L. paracasei BL23. 
4.3.1 Development of co-expression vectors 
Engineered Lactobacillus producing either surface-anchored ARP1 or ARP3 were previously 
constructed and shown to be therapeutically effective in the rotavirus infection mouse model. 
There are limitations for one VHH fragment targeting a single epitope due to reduced cross-
reactivity to circulating viral serotypes and potentially viral escape mutants. Therefore, we 
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believed that targeting multiple epitopes might improve the efficacy. To generate 
Lactobacillus expressing two rotavirus-specific VHH fragments (ARP1 and ARP3) in 
secreted and surface anchored forms, could certainly increase the binding to rotavirus and 
aggregation (due to binding to distinct epitopes). Additionally, if the virus acquires mutation 
on one binding site, the other VHH would retain its binding ability to the virus. Three distinct 
double expression cassettes were designed where the ARP1 and ARP3 were produced both 
secreted (pAF1200) in the medium, both covalently anchored (pAF1400) on the cell surface, 
or one secreted and the other anchored (pAF1300). To distinguish the co-produced ARP1 and 
ARP3 by Lactobacillus, different tags were selected and fused to each of them.  
4.3.2 Binding activity of co-expressed VHHs 
The expression and surface display of anchored ARP1 and ARP3 fragments on L. paracasei 
BL23 cells was verified by Western blot and flow cytometry. The level of expression as 
determined by Western blot densitometry was similar between co-expressor lactobacilli and 
lactobacilli producing one VHH fragment. Both VHH fragments were shown to be displayed 
in equal amounts on the surface of lactobacilli producing one or two fragments by flow 
cytometric analysis.  
Furthermore, anchored ARP1 and ARP3 produced by lactobacilli were shown to bind to all 
the tested strains of human and simian rotavirus in flow cytometry. Culture supernatant from 
lactobacilli producing secreted ARP1 and ARP3 were also broadly cross-reactive against 
human and simian rotavirus strains in ELISA.  
As a pediatric pathogen, rotavirus cause severe diarrhea in infants and is associated with a 
high mortality rate. Co-expression of two distinct VHH antibody fragment in Lactobacillus 
could increase the chance of neutralization through binding to different epitopes of the virus, 
meanwhile decrease the cost of production since there is no need of growing distinct batches 
of single-expressor bacterial cultures. Due to the broad cross-reactivity with many G/P 
combinations and the reduced production cost, lactobacilli co-expressing antibody fragments 
represent an alternative therapy for the developing world where people are infected with 
various genotypes. 
Most importantly, these co-expression platforms were designed with different restriction sites 
flanking the VHH genes, which will facilitate the cloning and delivery of various other 
therapeutic peptides by lactobacilli in the future. In paper IV, this co-expression vector was 
used to express IL-21 and CD40L in the same bacteria.  
4.4 PAPER IV 
Our previous studies proved that IL-21/CD40L stimulation may be an effective therapy for 
IgA deficient patient [140, 154]. In this paper, we are evaluating the possibility of developing 
an IL-21/CD40L-based Lactobacillus delivery system to induce immunoglobulin production 
in the gastrointestinal tract from patients with IgAD. As a first step, we expressed IL-21(or 
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hybrid IL-21/4) and CD40L individually, or co-expressed IL-21 and CD40L in Lactoacillus 
paracasei BL23, and tested if they could induce IgA secretion in PBMCs.    
4.4.1 Lactobacillus constructs and expression of IL-21 (IL-21/4) and CD40L  
A hybrid IL-21/4 was designed to combine the receptor-binding ability of IL-21 and IL-4 
based on our previous studies which showed that IL-4 can potentiate the immunoglobulin-
production induced by IL-21 [140, 154]. The chimeric molecule (hybrid IL-21/4 protein), 
together with IL-21, were first cloned into the pAFβ100 vectors due to the same reason that 
we discussed in paper II (fewer extra amino acids on N-terminus after secretion). However, 
the expression level was not as good as we expected. Human IL-21 has not yet been 
expressed by prokaryotes except in E.coli as inclusion body protein. We put much effort into 
trying to express IL-21 in lactobacilli by using different signal peptides, promoters (inducible 
expression promoter), fusion to a tag or other protein (human serum albumin domain 
III)(Table 3). However, all the attempts failed except when we cloned IL-21 into our pAF100 
vector. This could possibly be attributed to the additional seven amino acids left at the N-
terminus of the cytokine following cleavage of the signal peptide in pAF100 or plasmid 
stability. However, a strong signal was also observed in the cell pellet extract, indicating that 
the secretion of IL-21 from lactobacilli could be further optimized. 
Table 3 Different strategies employed to try to express IL-21(IL-21/4) 
 Constructs Expression Secretion 
IL-21  
IL-21 secreted (extra N-ter aa) Yes, weak smear Yes, weak smear 
IL-21 anchored (extra N-ter aa) Yes, weak band Yes, weak band 
IL-21 his-tag (C) No No 
IL-21 his-tag (N) No No 
IL-21 secreted (direct fusion) No No 
IL-21 secreted (direct fusion his-tag C) No No 
IL-21 streptag N-terminal No No 
IL-21 secreted Usp45 P+SP a No No 
IL-21 secreted Sakacin P b Yes No 
IL-21 N-ter HSA-D3 fusion Yes, weak band Yes, weak band 
IL-21 C-ter HSA-D3 fusion Yes, weak band Yes, weak band 
IL-21/4  
IL-21/4 secreted (extra N-ter aa) Yes, weak smear Yes, weak smear 
IL-21/4 anchored (extra N-ter aa) Yes, weak band Yes, weak band 
IL-21/4 streptag N-terminal No No 
IL21/4 E-tag secreted No No 
All the constructs were made in pAFβ100 or pAFβ900 vector which based on pIAβ8 plasmid. Except a in 
pAF100 and b in pVPL3017 [194]. P: promoter; SP: signal peptide. HSA-D3: human serum albumin domain III. 
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Human CD40L (with an E-tag fused at the C-terminal) was expressed anchored on the 
surface of Lactobacillus using the pAF900 vector, and surface display was confirmed by flow 
cytometric analysis. It is worth mentioning that 45% of the bacterial cells were not stained 
with the anti-E-tag antibody while only 14% were not stained for the positive control 
Lactobacillus expressing ARP1. We showed that approximately 57% of the bacteria lost their 
plasmid during growth in liquid, antibiotic supplemented MRS, which corresponds to the 
flow cytometric results. It indicates that the low IL-21 expression level could also be due to 
plasmid loss.  
The co-expression cassette developed in paper III was used to simultaneously produce both 
secreted IL-21 and anchored CD40L on the surface of lactobacilli. The aim of the co-
expression is to have both IL-21 and CD40L delivered at the same time to naïve B cells in the 
intestine. This moment could happened in the intestine when the intestine-resident dendritic 
cells sample bacteria in the lumen through transepithelial dendrites, or the live bacteria are 
transported across the epithelial barrier through M cells in the Peyer's patches [195].  
The co-expression cassette for IL-21/CD40L (pAF1300) is a fusion of pAF100 and pAF900 
cassettes in tandem, which have exactly the same promoter and terminator. However, the 
attempt of constructing lactobacilli co-expressing IL-21/4 and CD40L was not successful and 
resulted in loss of either IL-21/4 or CD40L gene expression probably due to plasmid 
rearrangement. Although such plasmids were previously shown to successfully express two 
VHH antibody fragments in paper III, rearrangement of the vector between the homologous 
sequences could possibly increase when the Lactobacillus strain is facing the pressure on 
growth caused by expressing human cytokines. The CD40L gene could be fused with another 
promoter and terminator to prevent rearrangement between homologous regions in the co-
expression vector.  
4.4.2 Bioactivity test of IL-21 (IL-21/4) and CD40L  
The lactobacilli expressing IL-21 (IL-21/4) and CD40L were tested for their ability to induce 
IgA switching in PBMCs from a healthy donor or IgAD patients' by using a single cell 
ELISPOT assay. The 10-fold concentrated supernatant of L. paracasei expressing IL-21/4 
using pAFβ100 stimulated both IgG and IgA production in a healthy donor and IgA 
production in two IgAD patients’ PBMCs. The concentrated supernatant of L. paracasei 
expressing IL-21 using pAFβ100 failed to stimulate IgG or IgA production in PBMCs 
probably due to a low expression level of IL-21 in the supernatant even after concentration. 
However, the concentrated supernatant of L. paracasei expressing IL-21 using pAF100, with 
higher level of IL-21, could stimulate both IgG and IgA production in healthy donor PBMCs. 
The Lactobacillus producing anchored CD40L along with the commercial recombinant 
human IL-21 was also shown to induce both IgG and IgA production in a healthy blood 
donor’s PBMCs.  
Our results thus showed that Lactobacillus produced IL-21, IL-21/4 and anchored CD40L are 
bioactive. This could eventually lead to a therapy where orally administered lactobacilli 
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producing both surface anchored CD40L and secreted IL-21 would induce IgA switching in 
B cells from IgAD patients and ultimately induce secretion of IgA in the mucosal tissues. 
Intestinal biopsies from IgA deficient patients will be prepared in future, both as whole tissue 
and single cell suspensions, stimulated with Lactobacillus delivering CD40L and IL-21 (or 
IL-21/4) to investigate cytokine mediated IgA production.   
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5 CONCLUSIONS  
The aim of this thesis is to explore the possibility of using lactobacilli as vectors for delivery 
of peptides in the gastrointestinal tract for therapy against type 2 diabetes and other immune-
related diseases. 
In paper I, a trypsin cleavable oligomers–pentameric GLP-1 was successfully expressed both 
in a secreted form and anchored on the surface of L. paracasei BL23. The pentameric GLP-1 
proved to be bioactive both in vitro and in the intestine of diabetic rat following digestion by 
intestinal trypsin. When the lactobacilli were given by gavage to the diabetic rats, the non-
expressor L. paracasei BL23 showed a significant anti-diabetic effect but GLP-1 expression 
did not provide an additional insulinotropic effect.  
In Paper II, the secreted and surface anchored mouse IL-22 was expressed by L. paracasei 
BL23. The biological activity of IL-22 produced by Lactobacillus was demonstrated in vitro. 
In paper III, a co-expression vector to produce two rotavirus-specific VHH antibody 
fragments in Lactobacillus was constructed. VHHs were expressed in secreted and surface 
anchored forms and their ability to bind to various rotavirus serotypes was demonstrated.  
In paper IV, IL-21 (or hybrid IL-21/4) and CD40L were expressed individually, or co-
expressed in L. paracasei BL23. We showed that Lactobacillus expressing IL-21, IL-21/4 
and CD40L individually are bioactive in inducing IgA secretion in PBMCs from healthy 
donors.  
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6 FUTURE PERSPECTIVES 
The present thesis advanced the knowledge on the use of Lactobacillus for delivery of 
therapeutic peptides in the GI tract with a focus on the metabolic disorder (type 2 diabetes) 
and immune-related diseases (GVHD, IgAD).  
To successfully deliver the peptide drugs in the GI tract, at least three main issues need to be 
considered. First, the stability of the peptide, since most of the peptides are susceptible to 
gastrointestinal proteases. We expected that Lactobacillus in situ delivery could reduce the 
peptide exposure to gastric acid, bile and digestive enzymes [196, 197]. Moreover, in paper I, 
we manipulated the 5×GLP-1 sequence to utilize the intestinal trypsin for releasing bioactive 
GLP-1 peptides. This strategy could be applied for Lactobacillus delivery of other peptides 
with a simple structure in the future. For the cytokines (paper II and IV) with more complex 
structure, bioactive cytokines were successfully expressed by lactobacilli without any amino 
acid modifications. Further optimization of the amino acid sequence could be performed in 
order to increase their stability in the GI tract provided that more knowledge on the cytokine 
structure is available. 
Secondly, the peptide absorption in the GI tract is generally low due to their high molecular 
weight and low lipophilicity [198]. Low bioavailability of many orally delivered peptides 
could be partly attributed to the low permeability of the intestinal barrier [199]. Various 
absorption enhancers and cell penetrating peptides have been investigated before [200], and 
we also tried to fuse a 16 amino acid hydrophobic penetratin domain [201] at the C-terminus 
of GLP-1 (paper I, unpublished data). However, a lower bioactivity of the peptide was 
observed in vitro compared to the original GLP-1, indicating that the efficacy of the 
therapeutic peptide might be affected by the fused hydrophobic peptide. Future studies of oral 
peptide delivery should still focus on enhancing the absorption from the GI tract.  
Lastly but most importantly, the amount of peptides that we can deliver to the gut is probably 
not enough due to the low expression level of our Lactobacillus delivery system. As in paper 
I, Lactobacillus gavage can deliver a maximum of 1.5 µg GLP-1 per rat, but the effective 
dose is at the mg level. The attempt of delivery of therapeutic peptides (GLP-1) was not as 
successful as delivery of antibody fragment (VHH) against intestinal infections [39-41] in 
vivo, which could be due to the following reasons: 1) for neutralization of pathogens, 
antibody fragments are not required at such a high level; 2) the antibody neutralization takes 
place in the gut lumen, but the therapeutic peptides need to cross the epithelial barrier to 
reach their receptors. Therefore, the expression system in lactobacilli should be improved in 
the future in order to increase their capability to deliver large amount of peptides.  
Our current expression system in lactobacilli has a constitutive expression promoter which 
controls the expression of apf gene. This promoter should be strong since APF is one of the 
most abundant secreted proteins from Lactobacillus crispatus [202]. Therefore, it might not 
be that promising to explore additional promoters which could drive higher expression level. 
Low expression could also be due to that the expressed protein is an extra metabolic burden 
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for the bacteria. In the future, we might need an inducible promoter in our Lactobacillus 
delivery system, to reach a high expression level. The two currently best characterized 
inducible expression systems in lactobacilli, the NICE system [203] and the sakacin-based 
expression system [21] are not tightly controlled in many Lactobacillus strains, resulting in 
leakage which lead to a final low expression level. A better choice could be an inducible 
expression system based on riboswitches, which is a regulatory domain typically found in the 
5´UTR region of mRNA, controlling the downstream gene expression at the translational 
level by binding small metabolites [204, 205]. Synthetic riboswitches could be designed to 
bind small metabolites (vitamin B12, thiamin pyrophosphate, nicotinamide etc.) in the GI 
tract and turn on the expression of peptides from engineered lactobacilli.   
The selection of a strain that closely adheres to the intestinal epithelium and persist for a 
longer period might also increase the efficacy of the Lactobacillus delivery system for 
therapeutic peptides. Although the orally administrated probiotic lactobacilli only transiently 
colonize the intestinal tract [206], some strains like L. rhamnosus GG can persist for 
prolonged periods (up to two weeks depending of the individual) than others [18, 206-208] 
and therefore, should be a more appealing strain to deliver peptides. In addition, therapeutic 
peptides could be expressed by an indigenous Lactobacillus strain isolated from the animals 
since the strain should establish itself better in the gut when evaluating the therapeutic effect 
in animal model [209]. The selection of the Lactobacillus strains is however highly 
dependent on their transformability and the protocol of transformation might need to be 
established for each strain. 
Plasmid loss was observed during the growth of lactobacilli producing cytokines (paper II 
and IV), and it might be one of the reasons leading to a lower expression level of these 
cytokines. Considering that the plasmid loss rate will be even higher when delivered in the GI 
tract, chromosomal integration of the expression cassette is preferable before in vivo testing in 
animal models and is a prerequisite for therapeutic applications in human. We tried to 
integrate the IL-22 gene on the chromosome using site specific chromosomal integration 
method as previously developed [30]. This method is however time consuming and we were 
not successful. We are also trying other methods for genomic integration of cytokine genes, 
like using a replicable plasmid to carry out homologous recombination, and then using 
another plasmid carrying the CRISPR/Cas9 system [194] to select the bacteria with an 
inserted gene. One problem could occur during the attempt of chromosomal integration: 
Since lactobacilli prefer to stop dividing in the medium with antibiotic rather than keeping the 
cytokine expressing plasmid, this probably means the cytokine expression causes a very high 
stress for the bacteria and therefore, the chromosomal integration is likely to fail too. Even if 
integration is achieved, the strain might try to avoid expressing the cytokine through other 
methods like point mutations or genomic rearrangements that lead to gene deletion. Thus, as 
we discussed before, the design of a tightly controlled inducible expression cassette is also 
crucial for delivery of peptides such as cytokines which are “toxic” for lactobacilli. The 
lactobacilli should be induced to express cytokines in the GI tract; and higher or more 
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frequent dose of the Lactobacillus could be given to compensate for the loss of expressing 
strains in the GI tract.  
When the engineered lactobacilli with the expression cassette integrated on the chromosome 
will eventually be used therapeutically in humans, a biological containment system to avoid 
the release of the modified lactobacilli into the environment will be required. This system will 
make bacteria able to grow in the lab but die in the environment, usually controlled by a 
substance which occurs in low amounts or is absent in the nature. For instance, a thymidylate 
synthase (thyA)-mutant strain cannot survive in a natural environment because thymidine 
supplement is critical for their life [210, 211], or strains that cannot survive in the absence of 
unnatural amino acids [212, 213]. 
To increase the expression level, characteristics of Lactobacillus which do not favor cytokine 
expression, could potentially be eliminated using a powerful genomic editing tool. We have 
been able to use the single-stranded DNA recombineering (SSDR) assisted with the 
CRISPR/Cas9 system [194] to knock out the LDH-1 (Lactate dehydrogenase) gene in L. 
paracasei BL23. Furthermore, due to the complexity of the Lactobacillus metabolic system, a 
random selection library is needed to tailor the bacteria for expressing different peptides. 
Until now, the CRISPR/Cas9 system can only be used as a selection method rather than a real 
genomic editing tool in prokaryotes, mainly because the bacterium is lacking the NHEJ 
pathway to repair the double strand break made by CRISPR/Cas9. In the future, an efficient 
gene knockout library could be established at the genome scale by creating a built-in NHEJ 
pathway (which has already been demonstrated in E. coli [214]) in lactobacilli to facilitate the 
use of the CRISPR/Cas9 system. 
The most surprising result observed in paper I is the significant anti-diabetic effect of L. 
paracasei BL23. L. paracasei BL23 is a commonly used laboratory strain for expression of 
recombinant proteins due to its high transformation rate. The exact origin of the strain is still 
unclear due to historical reasons [182, 183], and it probably does not form a stable population 
in the human GI tract. Little work has been performed regarding the probiotic properties of 
this specific strain [215] but other L. paracasei /casei strains have shown versatile probiotic 
effects including an anti-diabetic effect in vivo [216-218]. L. paracasei BL23 itself might be 
used in the future as an alternative treatment for type 2 diabetes. It will also be interesting to 
study the mechanism involved in the anti-diabetic effect of lactobacilli in order to select 
better strains or derived products.  
Another concern is whether the expression of therapeutic peptides, especially on the surface 
of lactobacilli, influences the probiotic effect or not. The GLP-1 secreted strain “lost” the 
antidiabetic effect compare to the wild type strain in paper I. Many studies have shown 
probiotic activities with killed or lysed lactobacilli [219, 220], indicating that some unique 
cell wall constituents or cell surface protein may contribute to this effect. The expression of 
peptides may influence the surface structure, further influencing its colonization and probiotic 
effect. Considering the safety and efficacy of engineered lactobacilli, all of the strains should 
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undergo strict quality check (genomic sequencing or in vitro probiotic assay including 
adhesion) to make sure that all the probiotic properties still exist before the clinical trial.  
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